Member Exclusive NEWS ROUND-UP

Cell therapy weekly: FDA issues statement marking halfway point in enforcement period for unproven regenerative medicine therapies

This week: Editas and BlueRock combine proprietary technology to develop engineered cell therapies and tissue-softening enzyme supports corneal regeneration.

Go to the profile of RegMedNet
Apr 04, 2019
0
0

Please sign in or register for FREE

No comments yet.